Thyrocare Q1 FY27 results: Board meet on Jul 23, 2026

Board meeting scheduled for July 23

Thyrocare Technologies Limited has given prior intimation to NSE and BSE about a meeting of its Board of Directors. The meeting is scheduled for Thursday, July 23, 2026. The main agenda is to consider and approve the company’s unaudited standalone and consolidated financial results for the quarter ended June 30, 2026 (Q1 FY27). Such board approvals are a standard step before quarterly results are filed with stock exchanges. The intimation also clarifies the compliance framework the company is following for insider trading controls. Investors typically track these dates because they indicate when financial performance updates will be released.

Q1 FY27 results approval is the key agenda

The company’s stated primary item is the approval of unaudited financial results for Q1 FY27. This means results for the quarter ended June 30, 2026 will be placed before the board. The filing does not provide Q1 FY27 numbers yet. It only sets out the process and the schedule. The disclosure also signals that the company intends to communicate the results formally to the exchanges after board consideration. For market participants, the board meeting date often becomes the anchor event for near-term price action and trading volumes.

Trading window shut since July 1

Thyrocare disclosed that the trading window for dealing in the company’s equity shares has been closed since July 1, 2026. The restriction applies to all Designated Persons and their immediate relatives. The closure is stated to be in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015 (as amended). It is also aligned with the company’s internal code of conduct to regulate, monitor, and report trading by Designated Persons and their immediate relatives. Trading window closures are typically implemented ahead of price-sensitive disclosures such as quarterly results. This is meant to reduce the risk of trading on unpublished price sensitive information.

When the trading window will reopen

The company said the trading window will reopen 48 hours after the declaration of the unaudited financial results for the quarter ended June 30, 2026 to the exchanges. The disclosure links reopening explicitly to the timing of results declaration. This provides a clear compliance timeline for insiders and connected persons who fall under the code. For investors, it also indirectly indicates when management expects the results communication process to conclude.

Earnings call at 6:00 PM IST

Thyrocare has also announced an earnings conference call on July 23, 2026, at 6:00 PM IST. The call is scheduled to discuss unaudited financial results for Q1 FY27. Senior management, including Chairman Rahul Guha and CFO Vikram Gupta, will lead the interaction. The company has provided dial-in and webcast options for participants. Earnings calls are typically used to explain quarterly performance, operational trends, and key business drivers.

Dial-in and webcast details disclosed

The conference call details provided include universal access numbers and links for registration and webcast. These details allow retail and institutional investors to join. The company shared a registration URL and a webcast link hosted by Chorus Call. The inclusion of both dial-in and webcast options broadens accessibility. The timing also suggests the results discussion will follow after the board meeting agenda is completed.

FY26 performance and AGM approvals

At its 26th AGM held on June 30, 2026, Thyrocare reported a 79% year-on-year increase in consolidated profit to ₹162.85 crore for FY26. Consolidated revenue for FY26 rose 21% year-on-year to ₹829.04 crore. The company also reported processing over 210 million tests during the year. Shareholders approved the adoption of audited standalone and consolidated financial statements for the year ended March 31, 2026. The AGM disclosure also noted that the Independent Auditors’ Reports carried no qualifications, reservations, or adverse remarks.

Dividend and leadership items approved at AGM

Shareholders declared a final dividend of ₹7.00 per equity share and confirmed the payment of an interim dividend of ₹7.00 per equity share (pre-bonus issue). The interim dividend was stated as equivalent to ₹2.33 per equity share post bonus adjustment, on shares with a face value of ₹10 each. The AGM also approved the re-appointment of Mr. Rahul Franklin Guha as Chairman, Managing Director and Chief Executive Officer effective May 04, 2027, along with his remuneration. These items are typically tracked by investors for clarity on capital returns and leadership continuity. The company’s communications therefore combine quarterly result scheduling with broader governance disclosures from FY26.

Market snapshot and recent quarterly reference points

The data shared includes multiple market snapshots, including ₹552.65 (-1.03%) and ₹554.20 (-0.67%), along with an intraday range shown as 546.40 and 558.50. Another snapshot lists the current price as ₹514, with Stock P/E at 50.9 and dividend yield at 1.85%. Separately, a quarterly table for the period labelled Jun 25 shows total revenue of ₹193.03 crore, net income of ₹38.93 crore, and diluted normalized EPS of 2.44 (all figures in crores except per share values). In the same set of data, a note says revenue of ₹193.03 crore represented a 3.14% QoQ increase and a 23.02% YoY growth. The company’s earlier Q1 FY26 press release also referenced revenue from operations of ₹193.03 crore and PAT including exceptional item of ₹38.06 crore.

Why these disclosures matter

The board meeting intimation and trading window closure are compliance-led disclosures, but they also set expectations on timing for Q1 FY27 results. The earnings call details indicate management intends to engage with investors on the same day at 6:00 PM IST. FY26 numbers disclosed at the AGM provide context on the company’s most recent annual profitability and revenue base, including ₹162.85 crore profit and ₹829.04 crore revenue. Quarterly reference points such as ₹193.03 crore revenue and ₹38.93 crore net income for the period labelled Jun 25 are part of the historical performance trail investors often compare against upcoming results. Taken together, the disclosures create a structured timeline for results approval, public dissemination, and post-results insider trading window reopening.

Conclusion

Thyrocare has scheduled its July 23, 2026 board meeting to consider Q1 FY27 unaudited standalone and consolidated results, alongside a 6:00 PM IST earnings call. The trading window has been shut since July 1 and will reopen 48 hours after results are declared to the exchanges.